Prostatic specific antigen for Prostate Cancer detection

International Braz J Urol

Volumn 35, Issue 5, 2009, Pages 521-529

  Nogueira, Lucas ^a   Corradi, Renato ^b   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Uveitis Section   (Brazil)

Author keywords

Biopsy; Diagnosis; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; BLOOD; HUMAN; MALE; PROSTATE TUMOR; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 77949560119     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382009000500003     Document Type: Review

References (43)

1. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002; 60: 458-63.
2. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, How-lader N, Eisner MP, Reichman M, Edwards BK: SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007
3. Smither AR, Guralnick ML, Davis NB, See WA: Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. BMC Urol. 2007; 7: 2.
4. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, et al.: Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101: 809-16.
5. Klein LT, Lowe FC: The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am. 1997; 24: 293-7.
6. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: The prostate specific an- tigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172: 1297-301.
7. Lilja H: A kallikrein-like serine protease in pros- tatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985; 76: 1899-903.
8. Piironen T, Nurmi M, Irjala K, Heinonen O, Lilja H, Lövgren T, et al.: Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing. Clin Chem. 2001; 47: 703- 11.
9. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, et al.: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol. 1990; 144: 1550-6.
10. Marks LS, Andriole GL, Fitzpatrick JM, Schul- man CC, Roehrborn CG: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006; 176: 868-74.
11. Fowler JE Jr, Bigler SA, Kilambi NK, Land SA: Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology. 1999; 53: 1175-8.
12. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al.: The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005; 103: 1092-5.
13. Myrtle J, Ivor L: Measurement of PSA in Serum by two Iimmunometric Methods (Hybritech Tan- dem-R/Tandem-E PSA). In: Catalona WJ (ed.), Clinical Aspects of Prostate Cancer. New York, Elsevier. 1989, pp. 161-71.
14. Bunting PS: Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta. 2002; 315: 71-97.
15. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al.: Effect of finasteride on the sensitivity of PSA for detect- ing prostate cancer. J Natl Cancer Inst. 2006; 98: 1128-33.
16. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ: Preoperative PSA and pro- gression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005; 66: 156- 60.
17. Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, et al.: Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology. 2007; 70: 748-52.
18. Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, et al.: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008; 26: 835-41.
19. Borer JG, Sherman J, Solomon MC, Plawker MW, Macchia RJ: Age specific prostate specific antigen reference ranges: population specific. J Urol. 1998; 159: 444-8.
20. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67: 316-20.
21. Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, et al.: Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007; 25: 431-6.
22. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-16.
23. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, et al.: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 1998; 160: 411-8; discussion 418-9.
24. Seaman EK, Whang IS, Cooner W, Olsson CA, Benson MC: Predictive value of prostate-specific antigen density for the presence of micrometa-static carcinoma of the prostate. Urology. 1994; 43: 645-8.
25. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al.: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994; 152: 2031- 6.
26. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al.: Estimation of pros- tatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992; 52: 3323-8.
27. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB: Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001; 58: 411-6.
28. Vickers AJ, Savage C, O'Brien MF, Lilja H: Sys- tematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009; 27: 398- 403.
29. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM: Is prostate-specific antigen veloc- ity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst. 2007; 99: 1510-5.
30. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al.: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993; 150: 100-5.
31. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, et al.: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991; 37: 1618-25.
32. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multi-center clinical trial. JAMA. 1998; 279: 1542-7.
33. Raaijmakers R, Blijenberg BG, Finlay JA, Rit-tenhouse HG, Wildhagen MF, Roobol MJ, et al.: Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol. 2004; 171: 2245-9.
34. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al.: Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000; 163: 1144-8; discussion 1148-9.
35. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996; 48(6A Suppl): 55-61.
36. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screen- ing. JAMA. 1995; 274: 1214-20.
37. Allard WJ, Zhou Z, Yeung KK: Novel immunoas- say for the measurement of complexed prostate- specific antigen in serum. Clin Chem. 1998; 44: 1216-23.
38. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, et al.: Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multi- center clinical trial. J Urol. 2003; 170: 1787-91.
39. Steuber T, O'Brien MF, Lilja H: Serum markers for prostate cancer: a rational approach to the literature. Eur Urol. 2008; 54: 31-40.
40. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al.: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001; 61: 6958-63.
41. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, et al.: Serum pro prostate specific antigen improves cancer detec- tion compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003; 170: 2181-5.
42. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, et al.: A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol. 2005; 174: 2150-3.
43. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H: Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem. 2001; 47: 1415-23.